The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
118761255 11876125 5 F 2015 20160217 20151229 20160728 EXP CA-JNJFOC-20151221562 JANSSEN 53.74 YR A F Y 89.00000 KG 20160728 OT CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
118761255 11876125 1 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 0 500 MG LYOPHILIZED POWDER
118761255 11876125 2 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 0 500 MG LYOPHILIZED POWDER
118761255 11876125 3 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 0 500 MG LYOPHILIZED POWDER
118761255 11876125 4 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 0 500 MG LYOPHILIZED POWDER
118761255 11876125 5 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 0 500 MG LYOPHILIZED POWDER
118761255 11876125 6 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 0 500 MG LYOPHILIZED POWDER
118761255 11876125 7 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 0 500 MG LYOPHILIZED POWDER
118761255 11876125 8 PS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) N FHM67012;FHM67012 103772 500 MG LYOPHILIZED POWDER
118761255 11876125 9 C MESALAZINE MESALAMINE 1 Unknown 0 500 MG UNSPECIFIED
118761255 11876125 10 C MELATONIN MELATONIN 1 Unknown 0 3 MG UNSPECIFIED
118761255 11876125 11 C ATIVAN LORAZEPAM 1 Oral 0 1 MG UNSPECIFIED

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
118761255 11876125 1 Crohn's disease
118761255 11876125 2 Crohn's disease
118761255 11876125 3 Crohn's disease
118761255 11876125 4 Crohn's disease
118761255 11876125 5 Colitis ulcerative
118761255 11876125 6 Colitis ulcerative
118761255 11876125 7 Colitis ulcerative
118761255 11876125 8 Colitis ulcerative

Outcome of event

Event ID CASEID OUTC COD
118761255 11876125 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
118761255 11876125 Abdominal pain
118761255 11876125 Arthropod bite
118761255 11876125 Constipation
118761255 11876125 Drug ineffective
118761255 11876125 Fistula
118761255 11876125 Frequent bowel movements
118761255 11876125 General physical health deterioration
118761255 11876125 Haematochezia
118761255 11876125 Off label use
118761255 11876125 Product use issue

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
118761255 11876125 1 20160217 0
118761255 11876125 2 20151223 0
118761255 11876125 3 20150916 0
118761255 11876125 4 20150915 0
118761255 11876125 5 20160217 0
118761255 11876125 6 20150916 0
118761255 11876125 7 20150915 0
118761255 11876125 8 20151223 0